Hemophilia is a rare congenital bleeding disorder that develops due to a complete or partial deficiency of specific blood coagulation proteins [5]. Specifically, hemophilia A involves a deficiency in factor VIII, while hemophilia B is characterized by a deficiency in factor IX, both stemming from pathogenic variants in their respective genes [5]. Because these factors are essential for proper blood clotting, individuals with these conditions may experience prolonged bleeding after injuries, surgeries, or spontaneous episodes. Managing this complex condition requires careful medical oversight by hematologists and multidisciplinary care teams [5].
Recognizing Symptoms and Bleeding Manifestations
The clinical presentation of congenital coagulation disorders can vary widely depending on the severity of the deficiency. Frequent hemorrhagic events commonly include nosebleeds, superficial and deep hematomas, and bleeding into the joints, known as hemarthrosis [3]. Additional manifestations can involve gastrointestinal bleeding and blood in the urine [3]. In some instances, bleeding events can occur in unusual or unexpected sites, such as the intestinal wall, potentially leading to acute or subacute bowel obstruction due to intramural hematomas [3]. Joint health is a major focus for patients and caregivers, as recurrent bleeding and related pain can significantly impact overall mobility and quality of life [2].
Acquired Hemophilia and Unique Clinical Challenges
While most cases are inherited, rare variations also exist. Acquired hemophilia A is a rare hemorrhagic condition caused by the spontaneous development of autoantibodies that inhibit factor VIII function [4]. It predominantly affects older adults who often manage multiple concurrent health conditions, presenting a high risk for life-threatening bleeding episodes [4]. Managing acquired hemophilia typically involves two main strategies: eradicating the inhibitor using immunomodulatory therapies and controlling active bleeding through the use of bypassing agents [4]. Modern therapeutic approaches, including agents like emicizumab, have also provided alternative ways to manage bleeding prophylaxis in complex clinical scenarios [4].
Treatment Options and Factor Replacement Therapy
The core of managing congenital hemophilia A and B centers on the appropriate use of specific concentrates containing the deficient blood-clotting factors [8]. To effectively treat bleeding symptoms and prevent long-term joint disability, clinicians calculate the precise amount of factor to infuse based on several biological and patient-specific parameters [8]. These include the patient's body weight, the biological half-life and yield of the infused factor, and the exact location and severity of the hemorrhage [8]. International clinical practice guidelines emphasize a structured, evidence-based approach to support hematologists, pediatricians, and patients in making informed treatment decisions [5].
Addressing Overall Health and Body Weight
Comprehensive hemophilia care extends beyond strictly managing factor levels to address broader health and lifestyle factors. For instance, maintaining overall wellness and managing body weight are important components of long-term care, as excess weight can place additional stress on already vulnerable joints [1, 2]. Patients often report goals focused on improving general health, increasing energy levels, and reducing health risks, while healthcare providers recognize that weight management plays a meaningful role in shaping future health outcomes and life expectancy [1, 2]. Integrating nutritional and physical therapy support into specialized hemophilia treatment centers helps address these multifaceted patient needs.
Sources
- 1. Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US haemophilia treatment centre professionals
- 2. Awareness, Care and Treatment In Obesity maNagement to inform Haemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a survey of US patients with haemophilia and obesity (PwHO) and their partners and caregivers
- 3. Rare and unusual bleeding manifestations in congenital bleeding disorders: an annotated review
- 4. Anticoagulation for Stroke Prevention after Restoration of Haemostasis with Emicizumab in Acquired Haemophilia A
- 5. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology
- 8. Treatment of hemophilia